Literature DB >> 30657019

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Tjalf Ziemssen1.   

Abstract

Proceedings of an Almirall-sponsored satellite symposium held at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, Germany, 10 October 2018.

Entities:  

Keywords:  THC:CBD oromucosal spray; multiple sclerosis spasticity treatment; observational studies; randomized controlled trials

Year:  2019        PMID: 30657019     DOI: 10.2217/nmt-2018-0048

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  1 in total

Review 1.  A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain.

Authors:  Michael A Überall
Journal:  J Pain Res       Date:  2020-02-14       Impact factor: 3.133

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.